Mental health

AI brain partnership
#AI #Drug discovery #Innovation #Mental health #Partnership

Partnership targets hard-to-diagnose mental health conditions 

Pangaea Data has been awarded a strategic partnership by the newly established Mental Health Research for Innovation Centre (M-RIC).   Pangaea is a provider of a novel artificial intelligence (AI)-driven product for characterising patients by automatically discovering clinical signatures for 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and… Read More

#News

Big Ben and Houses of Parliament
#Cancer research #Drug discovery #Funding #Mental health #UK government

Cancer research to get £22.5 million share of UK fund

The UK government has promised that patients will benefit from cutting-edge new treatments with the introduction of a Vaccine Taskforce style approach to tackling health challenges.  The government has committed over £113 ($135) million to fund research into four healthcare missions – cancer, obesity, mental health and addiction. Building… Read More

#Cancer Research #News

#Interview #Mental health #Neuroscience #Precision psychiatry #Psychiatry #Psychiatry Consortium #Target identification #Target validation

Target validation in psychiatry: addressing unmet therapeutic needs

The Psychiatry Consortium and the British Neuroscience Association recently published their 'Guiding Principles for Robust Target Validation in Psychiatry'. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic… Read More

#Exclusive Content

Magic mushrooms
#Depression #Mental health #Psilocybin #Psychedelics #The New England Journal of Medicine #Treatment-resistant depression #Trial data

Study shows ‘magic mushrooms’ could treat depression 

Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind.  The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). Read More

#News #Trending News

Patient reported outcomes
#Biomarkers #Mental health #Neurodegenerative disorders #Neurology #Neuroscience #Psychiatry

The rise of digital biomarkers in neuroscience drug development 

Listen to this article on the DDW Podcast: Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.  Increasingly, digital biomarkers are becoming more effectively used in the discovery and… Read More

#Editor's Choice #Exclusive Content

#Drug development #Funding #Mental health

Funding completed to develop psychedelic medicine breakthroughs

Beckley Psytech has completed Series B financing, raising $80 million from venture capital (VC) investors to fund its research programmes. The financing was initially set at $50 million and was upsized to $80 million due to interest from investors in broadening and accelerating the clinical development of Beckley Psytech’s research… Read More

#News

#Biosciences #Life sciences #Mental health #Psychedelics

Early success on psychedelic healthcare investments

Neo Kuma Ventures has invested in seven innovative healthcare companies. The initial investments have proved successful with three of the seven companies going public this year, yielding between +180% and +680% return on initial investment. Following the launch of its fund in December 2020, Neo Kuma has invested more than… Read More

#News